Myasthenia Gravis Complement Inhibitor Meets Primary Endpoint in Phase III Trial

(MedPage Today) — SAN FRANCISCO — Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (MG), topline data from the phase III PREVAIL…